Literature DB >> 31738648

The association of cognitive performance and IL-6 levels in schizophrenia is influenced by age and antipsychotic treatment.

Rafael Ribeiro-Santos1, Salvina Maria de Campos-Carli1, Rodrigo Ferretjans1, Andrea Teixeira-Carvalho2, Olindo Assis Martins-Filho2, Antonio Lucio Teixeira1,3, João Vinícius Salgado1,4,5.   

Abstract

Aims: Recent findings suggest that cognitive impairment can be associated with inflammation and immune changes in schizophrenia. We aimed to study possible associations between cytokine levels and cognitive performance in a sample of patients with schizophrenia.
Methods: Cognition was assessed with the brief assessment of cognition in schizophrenia in 63 clinically stable outpatients with schizophrenia. Blood was collected and cytokines (IL-2, IL-4, IL-6, IL-10, IL-17A, TNF-α, IFN-γ) were measured by cytometric bead array method. Psychopathological scales were also applied.
Results: IL-6 correlated negatively with general cognitive performance (rho = -0.395, p = .017) and positively with antipsychotic dose (rho = 0.412, p = .004). Multiple regression analysis showed that cognitive performance is associated with age and antipsychotic dose (p = .000 and p = .033).
Conclusion: The association between IL-6 levels and cognitive performance is dependent on age and antipsychotic dose.

Entities:  

Keywords:  IL-6; Schizophrenia; cognition; inflammation

Year:  2019        PMID: 31738648     DOI: 10.1080/08039488.2019.1688389

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  5 in total

1.  Evaluating the Hypothesis That Schizophrenia Is an Inflammatory Disorder.

Authors:  Brian J Miller; David R Goldsmith
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

2.  The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis.

Authors:  M Morrens; C Overloop; V Coppens; E Loots; M Van Den Noortgate; S Vandenameele; M Leboyer; L De Picker
Journal:  Mol Psychiatry       Date:  2022-04-28       Impact factor: 15.992

Review 3.  Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders.

Authors:  Anna Morozova; Yana Zorkina; Olga Abramova; Olga Pavlova; Konstantin Pavlov; Kristina Soloveva; Maria Volkova; Polina Alekseeva; Alisa Andryshchenko; Georgiy Kostyuk; Olga Gurina; Vladimir Chekhonin
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

4.  A Cross-Sectional Study on Associations Between BDNF, CRP, IL-6 and Clinical Symptoms, Cognitive and Personal Performance in Patients With Paranoid Schizophrenia.

Authors:  Egor Chumakov; Mariia Dorofeikova; Kristina Tsyrenova; Nataliia Petrova
Journal:  Front Psychiatry       Date:  2022-07-06       Impact factor: 5.435

5.  Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial.

Authors:  Renata Markiewicz; Agnieszka Markiewicz-Gospodarek; Beata Dobrowolska; Bartosz Łoza
Journal:  Neural Plast       Date:  2021-08-12       Impact factor: 3.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.